# PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

> **NCT03044743** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Yang Yang** · enrollment: 20 (estimated)

## Conditions studied

- Stage IV Gastric Carcinoma
- Stage IV Nasopharyngeal Carcinoma
- T-Cell Lymphoma Stage IV
- Stage IV Adult Hodgkin Lymphoma
- Stage IV Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT03044743
- **Lead sponsor:** Yang Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-07
- **Primary completion:** 2020-03
- **Final completion:** 2022-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03044743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03044743, "PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03044743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*